The Pistoia Alliance has appointed an advisory board to guide its strategy and provide insight and expertise from across the industry. The board will meet for the first time in London in March 2017. Confirmed appointees include:
- Alan Lewis (Board Director at Assembly Biosciences Inc., Board member at BıoMarın, President and CEO at Diavacs, Chairman of the Board at Batu Biologics, La Jolla, USA)
- Bill Burns (Switzerland; Shire; Mesoblast; Vestergaard; Wellcome Trust; Institute of Cancer Research)
- Bryn Roberts (Switzerland, Roche)
- Carl Peck (USA, FDA and now NDAPartners)
- David Feigel (USA, Amgen, UCSF and now NDA Partners)
- Kevin Dean (UK, Cisco Europe, now Chair AMRA, Digital Health consultant & Adjunct Professor, Maersk Institute, Denmark)
- Mike Farrar (UK, Head of NHS Trusts and now independent advisor, HC)
- Paul Fitzpatrick (UK/USA, HLInc Consultant)
- Shobie Ramakrishnan (USA, Genentech/AstraZeneca )
- Tim Irish (UK, NICE, NED)
- James P Sullivan (USA VP Discovery AbbVie)
- Steve Wooding (UK/USA, Head Global Commercial and Market Access Strategy, Janssen)